Pharmaceutical Executive
January 28, 2009
News Analysis
0
0
Big name patent expirations may be looming, but that's not stopping pharma companies from filing - and getting approved for - dozens of new patents. Pharm Exec looks at which companies are getting the most approvals, and how 2008 compared to previous years.
January 28, 2009
News Analysis
0
0
Astellas bumped its bid for CV Therapeutics to $1 billion, but analysts doubt the offer is high enough to get the biotech's board of directors to sign on the dotted line.
January 28, 2009
News Analysis
0
0
Pfizer hit hard with the surprise purchase of Wyeth. But will the pharma giant strike out in the long run? Analysts ponder the long and short-term ramifications of this monster acquisition.